Sanofi’s (NASDAQ: SNY) most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat […]
Sanofi’s (NASDAQ: SNY) Mixed Fortunes in MS Drug Trials Has Market Focus on Win Read More »
On Thursday, Sanofi (NASDAQ: SNY) raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected
HYDERABAD – French drugmaker Sanofi (NASDAQ: SNY) plans to invest 400 million euros ($437.24 million) in its global capacity center
Sanofi (NASDAQ: SNY) Eyes Major Expansion in India with $437 Million Investment Read More »
Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi’s (NASDAQ: SNY)
Sanofi (NASDAQ: SNY) Consumer Health Unit Attracts Interest from Bpifrance Read More »
On Wednesday, Sanofi (NASDAQ: SNY) and partner Regeneron (NASDAQ: REGN) won European Union approval for wider use of their Dupixent
Sanofi (NASDAQ: SNY) Win EU Approval for Dupixent in Chronic Lung Disease Read More »
BERLIN – French drugmaker Sanofi (NASDAQ: SNY) is nearing a decision to invest between 1.3 billion and 1.5 billion euros
Sanofi (NASDAQ: SNY) Plans Billion-Euro Investment in German Insulin Production Facility Read More »
